News & Updates

The combination of ipilimumab and nivolumab may provide a progression-free survival (PFS) benefit in patients with metastatic or unresectable melanoma who did not respond to anti-PD-1/anti-PD-L1 therapy, according to a small study presented at AACR 2022.

In solid organ transplant recipients with moderate symptoms of SARS-CoV-2 infection, early administration of a 3-day remdesivir course appears to effectively prevent COVID-19-related hospitalization as well as the clinical worsening of those who are hospitalized, according to a study.

Pregnant women with preconception venous thromboembolism (VTE) who have no exposure to any anticoagulant and those on low-molecular-weight heparin (LMWH) have the lowest risk of foetal adverse outcomes, reveals a study, which supports the recommendation of LMWH during pregnancy.

The addition of the monoclonal anti-interleukin-1β antibody canakinumab to the standard of care (SoC) regimen of platinum doublet chemotherapy and pembrolizumab in the first-line setting did not improve progression-free survival (PFS) or overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC), results of the phase III CANOPY-1 trial showed.